A new kind of cell therapy is moving from the lab straight into patients’ bodies. Scientists have created tiny, targeted lipid nanoparticles that deliver CAR‑T instructions directly to a person’s own immune cells, turning them into cancer‑fighting soldiers inside the body. This “in‑vivo” approach skips the costly, time‑consuming step of growing engineered cells in a lab, making the treatment potentially affordable and widely available. Pre‑clinical work in human‑engineered mice and rhesus monkeys showed that a single injection can generate CAR‑T cells within hours, wiping out nearly 100 % of harmful B cells from blood and tissues. In leukemia models, some animals experienced complete tumor disappearance. Remarkably, the B‑cell population that returns after treatment is mostly harmless “naïve” cells, while the disease‑causing “memory” B cells stay eliminated – a phenomenon researchers call an “immune reset,” which could lead to long‑term remission for autoimmune patients. Building on these results, Capstan Therapeutics launched a Phase I clinical trial in June 2025 to test safety, dosing and durability in humans. If successful, this off‑the‑shelf, in‑body CAR‑T platform could turn a cutting‑edge, specialist therapy into a routine option for cancer and autoimmune diseases, ushering in a new era of precise, efficient and inclusive medicine.
Read more